Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Update

Sutro Biopharma, Inc. (NASDAQ:STRO) saw a significant drop in short interest in February. As of February 27th, there was short interest totaling 517,388 shares, a drop of 19.8% from the February 12th total of 645,074 shares. Based on an average daily trading volume, of 100,424 shares, the short-interest ratio is presently 5.2 days. Approximately 6.5% of the shares of the stock are short sold. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 100,424 shares, the short-interest ratio is presently 5.2 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Sutro Biopharma in the second quarter valued at about $27,000. Savant Capital LLC purchased a new position in Sutro Biopharma in the 2nd quarter worth approximately $37,000. Bridgeway Capital Management LLC grew its position in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares in the last quarter. Invesco Ltd. raised its stake in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares during the period. Finally, Cerity Partners LLC lifted its position in shares of Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after purchasing an additional 66,372 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

STRO stock traded up $1.97 during midday trading on Monday, reaching $25.05. 44,209 shares of the company’s stock traded hands, compared to its average volume of 135,129. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $26.54. The business has a 50-day moving average price of $16.89 and a two-hundred day moving average price of $12.06. The company has a market capitalization of $213.21 million, a P/E ratio of -0.96 and a beta of 1.47.

Analysts Set New Price Targets

Several brokerages have recently commented on STRO. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. HC Wainwright lifted their target price on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Citizens Jmp upgraded Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective on the stock in a research report on Tuesday, January 20th. Wedbush restated a “neutral” rating and set a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $31.83.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.